Jade Biosciences, Inc. · NASDAQ:JBIO
Jade Biosciences — Investor Presentation (August 2025)
25 slides from Jade Biosciences's investor presentation, August 2025
Slide 1: Company Overview
Company Overview August 2025 NASDAQ: JBIO
Slide 2: Disclaimers
Disclaimers Forward Looking Statements Certain statements in this presentation, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities
Slide 3: Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases
Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases Cash and cash equivalents of $220.9 million*, expected to support operations through 2027, well beyond biomarker-rich JADE101 healthy volunteer data MOA Program Candidate Discovery IND-enabling Planned FIH Inte
Slide 4: JADE101: a potentially best-in-class anti-APRIL mAb for IgAN
JADE101: a potentially best-in-class anti-APRIL mAb for IgAN 4
Slide 5: Jade is developing a potentially best-in-class anti-APRIL mAb
Jade is developing a potentially best-in-class anti-APRIL mAb Estimated Current treatments do not adequately Anti-APRIL Mechanism has potential to be disease- $10B+ address the need for long-term disease- modifying therapy in class poised to be frontline treatment modifying, reducing pathogenic IgA
Slide 6: IgAN is a $10B+ potential market with need for effective and convenient therapies
IgAN is a $10B+ potential market, with a need for effective and convenient therapies for life-long treatment IgAN is typically diagnosed in young adults; higher proteinuria ~169K+ IgAN patients in the U.S., with 60-75% requiring is associated with greater risk of kidney failure treatment per interna
Slide 7: Proposed KDIGO updates position anti-APRIL class as foundational therapy in IgAN
Proposed updates to KDIGO guidelines position the anti- APRIL class as the foundational therapy in IgAN IgAN patients at risk Expanding Patient Population of progressive kidney function loss • Kidney biopsy recommended in all adults with proteinuria ≥0.5 g/d where IgAN is a possible diagnosis In all
Slide 8: JADE101: Ultra-high affinity, half-life extended mAb
JADE101: Ultra-high affinity, half-life extended mAb with potential for best-in-class activity and patient convenience Femtomolar APRIL Affinity + Half Life Extension Potentially best-in-class Potential for ≤ 6 injections Avoids unnecessary efficacy per year immunosuppression APRIL inhibitors demons
Slide 9: Reducing pathogenic IgA production by plasma cells is a potentially disease-modifying approach
Reducing pathogenic IgA production by plasma cells is a potentially disease-modifying approach for IgAN Broad B-cell depletion is ineffective in IgAN… …while targeted plasma cell modulation is highly effective. • B-cell depletion with rituximab (anti-CD20) failed to reduce Gd- • APRIL and dual APRIL
Slide 10: Selective APRIL inhibition resulted in numerically greater proteinuria reduction than dual APRIL/BAFF
Selective APRIL inhibition resulted in numerically greater proteinuria reduction compared to dual APRIL/BAFF in Phase 3 IgAN trials UPCR Δ from baseline (%, W36) Sibeprenlimab Atacicept Δ -51% Δ -42% (p < 0.0001) (p < 0.0001) 2.1 Sibeprenlimab Placebo Atacicept N=152 N=95 N=103 Placebo N=168 -7 Stud
Slide 11: Deeper APRIL suppression drives superior clinical efficacy
Deeper APRIL suppression drives superior clinical efficacy Sibeprenlimab Phase 2 Data • Highest proteinuria reduction and rates of clinical remission (proteinuria <0.3 g/day) for sibeprenlimab APRIL were accompanied by the deepest levels of APRIL suppression. • Safety profile consistent across dose
Slide 12: No clinical evidence that inhibiting BAFF provides additional efficacy beyond APRIL alone
No clinical evidence that inhibiting BAFF provides additional efficacy beyond APRIL alone in IgAN Phase 2 clinical trials Sibeprenlimab Zigakibart Atacicept Povetacicept MoA anti-APRIL anti-APRIL TACI-Fc Engineered TACI-Fc Status Phase 3 Phase 3 Phase 3 Phase 3 IgA Gd-IgA1 UPCR IgA Gd-IgA1 UPCR IgA
Slide 13: BAFF inhibition is accompanied by potential for significant long-term B cell depletion
BAFF inhibition is accompanied by the potential for significant long-term B cell depletion Long-term BAFF inhibition … whereas chronic APRIL inhibition significantly depletes B cells… does not impact circulating lymphocytes Zigakibart Lymphocytes (109/L) ~7-year belimumab data in SLE shows long-term
Slide 14: Potentially best-in-class properties of JADE101
Potentially best-in-class properties of JADE101 Ultra-high (fM) APRIL binding Novel IP for composition affinity of matter into mid-2040s • Binds APRIL to neutralize activity • Greater APRIL binding affinity than sibeprenlimab, zigakibart, povetacicept and atacicept De novo antibody discovery Half-li
Slide 15: JADE101 has femtomolar affinity and a slow off-rate superior to other anti-APRILs
JADE101 has femtomolar affinity and a slow off-rate that is superior to other anti-APRILs currently in development APRIL affinity by SPR is highly predictive of in vivo APRIL affinity potency to lower by SPR is highly serum IgA inpredictive humans of in vivo potency to lower serum IgA in humans 1000
Slide 16: JADE101 avoids high molecular weight complex formation
JADE101 avoids high molecular weight complex formation High MW complex formation can occur with mAbs binding trimeric proteins, such as APRIL. Avoiding high MW complexes potentially mitigates risks of immunogenicity and target mediated drug disposition (TMDD). MW - molecular weight, mAbs – monoclona
Slide 17: JADE101 exhibits a highly differentiated NHP PK/PD profile
JADE101 exhibits a highly differentiated NHP PK/PD profile >3X increased half-life compared to sibeprenlimab* in NHPs Accompanied by deep and prolonged IgA reduction T1/2 ~27d T1/2 ~7d JADE101 has the potential to extend dosing interval through low clearance via half-life extension, target-mediated
Slide 18: Minimizing injection burden is a critical advantage in lifelong IgAN treatment
Minimizing injection burden for patients is a critical advantage in lifelong IgAN treatment Reducing injection frequency is anticipated to be a valuable choice driver • IgAN typically affects young JADE101 Sibeprenlimab Atacicept Povetacicept Zigakibart adults who may require lifelong therapy • Fewe
Slide 19: Anticipated 1H26 HV data potentially positions JADE101 for accelerated development
Anticipated 1H26 HV data potentially positions PK, APRIL and IgA HV data will define the dose and schedule designed to fully suppress APRIL JADE101 for accelerated development throughout the dosing interval in IgAN patients. MOA Candidate IND Enabling Phase 1 Initiation Interim Healthy Volunteer Dat
Slide 20: Biomarker-rich, directly translational HV data supports accelerated clinical development
Biomarker-rich, directly translational HV data supports the potential to accelerate clinical development IgA reduction in HVs is highly correlated with IgA …and early IgA reduction further correlates with W36 UPCR reduction in IgAN patients at multiple time points… reduction, the anticipated endpoin
Slide 21: Pipeline beyond JADE101
Pipeline beyond JADE101 21
Slide 22: Additional Jade programs expected to focus on best-in-class product profiles
Additional Jade programs expected to focus on best-in-class product profiles in high-value autoimmune indications Autoimmune Potentially best- Potential rapid Limited Jade team indications with in-class and path to clinical competition expertise significant best-in- PoC expected market indication op
Slide 23: Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases
Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases Cash and cash equivalents of $220.9 million*, expected to support operations through 2027, well beyond biomarker-rich JADE101 healthy volunteer data MOA Program Candidate Discovery IND-enabling Planned FIH Inte
Slide 24: Current capitalization
Current capitalization Number of Shares* Common stock Shares outstanding 32,626,730 Preferred stock (as converted to 12,622,000 Common stock equivalents common stock) Pre-funded warrants 7,375,394 Common stock & common Total outstanding 52,624,124 stock equivalents *As of June 30, 2025 24
Slide 25: Thank you
Thank you www.JadeBiosciences.com | info@jadebiosciences.com NASDAQ: JBIO
Jade Biosciences — Investor Presentation (August 2025) on 6ix